View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 12, 2020updated 25 Nov 2021 11:25am

PeptiDream and Merck partner to develop Covid-19 therapeutics

Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.

Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

In April, PeptiDream launched a multi-pronged initiative to identify peptide candidates targeting various sites / regions of coronaviruses.

The partners intend to develop therapeutics with activity against the current coronavirus, as well as any future coronavirus outbreaks. The aim is to create drugs targeting several coronavirus strains.

PeptiDream noted that the partnership builds on the research collaboration and licence agreement signed between the companies in April 2015.

PeptiDream president and CEO Patrick Reid said: “We are excited to announce this partnership focused on the discovery and development of peptide candidates targeting multiple coronaviruses.

“Our wide-ranging collaboration continues to make exceptional progress and I am confident that together we can make an impact in combating this global challenge.”

Under the agreement, Merck will make an upfront payment to PeptiDream, which will also be eligible for select preclinical, clinical and regulatory milestone payments.

The Japanese company will also receive royalties on future sales of any therapeutics resulting from the collaboration; specific financial details were not disclosed.

Merck Discovery Chemistry research vice-president Emma Parmee said: “Our experience has shown that good science and strong collaborations are essential to develop medicines and vaccines, and that is especially true now in a global public health emergency.

“We look forward to working with scientists at PeptiDream to identify candidates targeting SARS-CoV-2 and other coronaviruses.”

Last month, Merck signed three separate Covid-19-focused agreements with Themis, IAVI and Ridgeback Biotherapeutics. These deals are for the development of potential Covid-19 therapies and a vaccine candidate.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology